Biotech patents are tricky. If you work with genes, living cells or new diagnostic tests, getting a patent means meeting both scientific and legal requirements and the two don’t always align.
On 8 October 2026, IP India released draft guidelines for examining biotechnology patent applications. Stakeholders have 15 days from the publication date to submit comments and suggestions.
If you’re a founder, researcher or patent applicant, this matters. The draft provides insight into how biotechnology patent applications may be approached during examination. So what are these guidelines meant to do and what should you watch for? Here’s a simple walkthrough.
The Draft Biotech Guidelines at a Glance
Think of the draft as a roadmap for examiners. It has 21 sections and covers the key tests every application faces: novelty, inventive step and industrial use. It also explains the exclusions under Section 3 of the Patents Act, 1970 that often affect biotech claims, such as natural substances, diagnostic methods and plants and animals.
Along the way, it includes 36 illustrative examples that show how a claim might be judged. It also covers biodiversity rules, sequence listings, unity of invention and depositing biological material. The draft also says examiners would have to share their search strings in their reports.
For applicants, the practical value of the draft lies in understanding the examination issues that may arise for biotechnology applications.
How Are Biotech Patent Applications Different From Others?
A bridge or a circuit is built from materials we can measure and repeat. Biotech works with living things. Cells, microbes, genes and biological processes can behave in ways that are hard to predict or describe. That raises questions an examiner may not face with a mechanical or electrical invention.
These differences can make the examination of biotech applications more technically specific than applications in some other technology fields. Others are special to biotech. Scientific advancement alone is not enough; the invention must also satisfy the applicable patentability requirements.
Patentability Basics Every Applicant Should Know
Before filing, it helps to know the core tests your biotech invention has to pass, so let’s start with the first one: novelty.
Novelty
Before anything else your invention has to be new. That sounds simple, but it takes real homework. Has this idea already been disclosed in a paper, a patent document or a public talk? If so, it may not count as new.
Biotech applicants should search widely before they file and check closely every earlier disclosure against what they plan to claim.
Inventive Step
Being new is only half the test. Your invention also needs an inventive step, meaning it can’t be an obvious move for someone skilled in the field.
So ask yourself two things. How does my invention differ from what’s already known? And why does that difference matter technically? Strong data in your application can help you answer both.
Industrial Applicability
A biotech invention also has to be useful in the real world. In patent terms, that means it can be made or used in an industry. Your application should say clearly how this would work.
Don’t just guess at a use. Give a specific, believable example, such as a gene sequence used to diagnose a particular disease. That can help support your application.
Also Read: Supreme Court to Examine Patent Term Adjustment in India: What Could It Mean for Patent Owners?
About Disclosure and Claim Clarity
A patent is a deal: you explain your invention fully and in return you get protection. In biotech, that explanation can be hard, because the science is complex. Your application must describe the invention clearly enough to support every claim you make.
Claims matter just as much. They actually define the scope of protection you are seeking. Keep them clear, tie them to what you actually described and make sure they cover patentable subject matter. Claims that reach too far, well beyond what you’ve shown, can often draw objections.
Biotechnology-Specific Patent Issues
Beyond the basic tests, biotech applications can raise special questions, so let’s look at the ones applicants should watch most closely.
Biological Material
If your invention uses biological material, expect questions about that material. Where did it come from? Applicants should disclose the source and geographical origin of biological material used in the invention as required under the applicable patent rules.
This matters most when you work with biological resources from India. Missing or incorrect details can cause real trouble. Check the disclosure and regulatory rules early on, so approvals and paperwork don’t slow down your application later.
Living Material and Discoveries
Finding something in nature is not the same as inventing it. Section 3(c) of the Patents Act covers this. It says the discovery of a living thing or a non-living substance that already exists in nature is not an invention.
So if your application involves natural biological material, you need to explain what makes the claimed subject matter more than a discovery of something already occurring in nature.
Ethics & Environmental Aspects
Some biotech inventions are larger than science. They can touch on ethics, public health or the environment.
Section 3(b) of the Patents Act does not allow inventions that go against morality or could seriously harm human, animal or plant life, health or the environment. So before you file, ask yourself if your invention could fall under this rule or any other exclusions and plan your response early.
Why the Draft Matters for Patent Applicants?
The draft is a good reason to review how you prepare biotech applications. Check your technical details, how broad your claims are and each patentability requirement. Also look for rules that apply specifically to biotech.
For applicants, the draft’s practical value lies in understanding how the Patent Office may approach biotechnology applications during examination.
The Draft Is Open for Public Comments
IP India wants to hear from you. The draft guidelines are open for comments and suggestions for 15 days from the date of publication. That means biotech companies, researchers and patent professionals can take part.
Why does it matter? Guidelines shape how applicants get ready for examination. People who work with biotech inventions often face practical challenges up close. Their feedback can point out unclear areas and help improve the final version. Since the window is short, read the draft soon and decide if you have something to share.
What Should Biotech Applicants Do Now?
Start by identifying the provisions that are most relevant to your technology and reviewing how they may affect examination of your application. If you are preparing a new filing, this can also help you identify areas that may require closer attention before submission.
Stakeholders should also review any subsequent notice or final version issued by IP India before relying on the draft as a reference for future filings.
The key takeaway is simple: the draft gives biotech applicants another reference point for understanding patent examination but the applications must still be assessed under the applicable patent law and requirements.
Frequently Asked Questions
1.) What patentability requirements apply to biotech inventions?
Ans:- Biotech inventions must satisfy requirements such as novelty, inventive step and industrial applicability, along with applicable exclusions under the Patents Act, 1970.
2.) How does Section 3 affect biotechnology patent applications?
Ans:- Section 3 excludes certain subject matter from patent protection, including discoveries of substances occurring in nature and other subject matter covered by specific exclusions.
3.) Are the draft biotech patent guidelines legally binding?
Ans:- No. The guidelines are still in draft form and do not replace the applicable patent laws and requirements.
4.) What should applicants disclose about biological material?
Ans:- Applicants using biological material should pay attention to requirements concerning the source and geographical origin of the biological material used in their inventions.
5.) Can stakeholders comment on the draft biotech guidelines?
Ans:- Yes. IP India has invited stakeholders to submit comments and suggestions within 15 days from the date of publication.